A Phase 1 interventional study of SUVN-I6107 and Placebo in Healthy, sponsored by Suven Life Sciences Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Suven Life Sciences Limited · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is 1) to investigate how safe and tolerable SUVN-I6107 is after a single oral dose at increasing dose levels and multiple oral doses at increasing dose levels, 2) to determine the pharmacokinetic (PK) profile after single and multiple ascending oral doses, 3) to investigate the effects of food on SUVN-I6107 pharmacokinetics and 4) to evaluate the pharmacodynamic (PD) effects of single and multiple ascending oral doses of SUVN-I6107 on quantitative electroencephalogram (qEEG) and event-related potential (ERP) assessments.
This research study is a randomized, single-center, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD), first-in-human study in healthy participants.
This study consist of 2 segments: Segment 1 will be the SAD portion and Segment 2 will be the MAD portion.
Segment 1 will include up to 5 sequential cohorts. Up to 40 healthy male or female subjects, ages 18 - 45 years (inclusive) old at screening will be enrolled.
Segment 2 will include up to 3 sequential cohorts. The dosing will be administered for 14 consecutive days. Up to 24 healthy male or female subjects, ages 50 to 80 years (inclusive) old at screening will be enrolled.
Suven Life Sciences Limited is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single ascending doses administered orally
Drug: SUVN-I6107 · Drug: Placebo
multiple ascending doses administered orally for 14 days.
Drug: SUVN-I6107 · Drug: Placebo
SUVN-I6107 Tablet
A look-alike tablet with no active ingredient.
Number of participants with treatment-related adverse events
Number of participants with adverse events (AE), discontinuations due to AE or serious adverse event \[SAE\], and withdrawals from the study due to AE.
Time frame: From Day 1 to Day 11 (Segment 1) and from Day 1 to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values
Descriptive statistics of QTcF for observed values and changes from baseline will be summarized at each scheduled time point.
Time frame: From Baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Blood Pressure
Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Pulse Rate
Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Body Temperature
Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Number of Participants With Clinically Significant Changes in Respiration Rate
Time frame: From baseline to Day 11 (Segment 1) and to Day 24 (Segment 2)
Changes in Columbia Suicide Severity Rating Scale (C-SSRS) Score
The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.
Time frame: From baseline to Day 24 (Segment 2)
Area under the concentration-time curve (AUC)
SUVN-I6107 concentrations levels will be assessed after single and multiple ascending oral doses.
Time frame: Day 1 and Day 14
Maximum observed concentration (Cmax)
SUVN-I6107 maximum observed concentration will be assessed after single and multiple ascending oral doses.
Time frame: Day 1 and Day 14
Time to reach maximum concentration (Tmax)
Time to reach maximum concentration will be assessed after single and multiple ascending oral doses.
Time frame: Day 1 and Day 14
Terminal half-life (t½)
SUVN-I6107 elimination rate will be assessed after single and multiple ascending oral doses.
Time frame: Day 1 and Day 14
Quantitative electroencephalogram (qEEG)
Change in absolute quantitative electroencephalogram (qEEG) power from predose to postdose.
Time frame: Day 1 (Segment 1); Day 7 and Day 12 (Segment 2)
Latency for parameter from the Active, Auditory Oddball Event-related potential (ERP) test
Change in latency (in milliseconds) for the P300 parameter from the Active, Auditory Oddball ERP test from predose to postdose.
Time frame: Day 1 (Segment 1); Day 7 and Day 12 (Segment 2)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Dec 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suven Life Sciences Limited